宫颈癌推量治疗模式:腔内近距离放疗与腔内联合组织间插植近距离放疗及立体定向体部放疗的剂量学比较
本研究回顾性识别24例宫颈癌腔内联合组织间插植近距离放疗推量计划,为每例额外创建腔内近距离放疗和立体定向体部放疗计划,比较靶区覆盖和危及器官剂量。结果显示腔内联合组织间插植近距离放疗较腔内近距离放疗靶区覆盖更优且危及器官剂量更低,作者认为其为首选推量模式。
要点
- 腔内联合组织间插植近距离放疗较腔内近距离放疗膀胱D2cc平均绝对降低1 Gy(相对剂量-19%),可达硬性约束。
- 无计划靶区外扩的立体定向体部放疗对危及器官EQD23-D2cc最低,但高危临床靶区D50%和D30%显著低于近距离放疗。
- 按靶区归一化时,腔内近距离放疗EQD210-D90%为6.62 Gy,无法达到覆盖目标。
核心结论
- 近距离放疗较无计划靶区外扩的立体定向体部放疗的关键剂量学优势是高危临床靶区D50%和D30%显著更高,增加靶区局部和适形剂量。
- 腔内联合组织间插植近距离放疗较腔内近距离放疗靶区覆盖显著更优且危及器官剂量更低,作者认为其是宫颈癌首选推量模式。
研究设计与样本
- 回顾性识别24例连续的腔内联合组织间插植近距离放疗推量治疗计划,为每例计划额外创建腔内近距离放疗和立体定向体部放疗计划,共研究72个计划。
- 未生成计划靶区或计划危及器官体积外扩,所有推量模式的 structures 完全相同。
- 采用两种归一化:(1)靶区归一化:处方7.1 Gy至高危临床靶区D90%;(2)危及器官归一化。
- 使用线性二次模型计算外照射和近距离放疗的等效2 Gy分次剂量,α/β分别取10(EQD210)和3(EQD23)。
主要发现
- 第一种归一化下,腔内近距离放疗计划的危及器官平均EQD23-D2cc显著更高,膀胱D2cc硬性约束无法达到。
- 腔内联合组织间插植近距离放疗使膀胱EQD23-D2cc平均绝对降低1 Gy(相对剂量-19%),可达硬性约束。
- 无计划靶区外扩的立体定向体部放疗对危及器官的EQD23-D2cc最低。
- 第二种归一化下,腔内近距离放疗的EQD210-D90%显著更低(6.62 Gy),无法达到覆盖目标。
- 无计划靶区外扩的立体定向体部放疗高危临床靶区D90%剂量最高,EQD210-D50%和D30%显著更低。
关键数值与推荐
- 靶区归一化处方:7.1 Gy至高危临床靶区D90%。
- 腔内联合组织间插植近距离放疗较腔内近距离放疗膀胱EQD23-D2cc平均绝对降低1 Gy(相对剂量-19%)。
- 腔内近距离放疗EQD210-D90%为6.62 Gy。
临床怎么用
- 原文结论认为腔内联合组织间插植近距离放疗是宫颈癌首选推量模式。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE / OBJECTIVE: This study compares the dosimetric plans of three distinct boost modalities in cervical cancer (CC): intracavitary (IC) with tandem/ovoids brachytherapy (BT), IC + interstitial (IS) BT, and Stereotactic-Body-Radiotherapy (SBRT). The aim is to determine the dosimetric impact in terms of target coverage and organ at risk (OAR) doses. MATERIALS AND METHODS: 24 consecutive IC + IS BT boost treatment plans were retrospectively identified. For each plan included, two additional plans were created: IC-BT and SBRT. Importantly, no planning target volume (PTV) or planning (organ at) risk volume (PRV) margins were generated, therefore all structures were identical for any boost modality. Two different normalizations were performed: (1) Normalization to the target: prescription of 7.1 Gy to the D90% (defined as the minimum dose covering 90%) of the high-risk clinical target volume (HR-CTV); (2) Normalization to the OARs. HR-CTV coverage and OARs sparing were compared. The equivalent doses in 2 Gy fractions (EQD2) of EBRT and BT for CTV-HR and OARs were calculated using the linear-quadratic model with α/β of 10 (EQD210) and 3 (EQD23), respectively RESULTS: A total of 72 plans were investigated. In the first normalization, the mean EQD23-D2cc (defined as the minimal dose of the 2 cc) of OAR was significantly higher in the IC-BT plans, and the bladder D2cc hard constraint could not be reached. IC + IS BT leads to a 1 Gy mean absolute decrease of bladder EQD23-D2cc (relative dose: -19%), allowing to reach the hard constraint. SBRT (without PTV) delivers the lowest EQD23-D2cc to the OAR. In the second normalization, IC-BT provides a significantly lower dose to the EQD210-D90% (6.62 Gy) and cannot achieve the coverage goal. SBRT (without PTV) yields the highest dose to the D90% of HR-CTV and a significantly lower EQD210-D50% and D30%. CONCLUSION: The key dosimetric benefit of BT over SBRT without PTV is a significantly higher D50% and D30% in the HR-CTV, which increases the local and conformal dose to the target. IC + IS BT vs. IC-BT provides significantly better target coverage and a lower dose to the OARs, making it the preferred boost modality in CC.
引用
- Benkhaled S, Diakité K, Jullian N, et al. Boost modalities in cervical cancer: dosimetric comparison between intracavitary BT vs. intracavitary + interstitial BT vs. SBRT. Radiat Oncol. 2023. PMID: 37381016. doi:10.1186/s13014-023-02295-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。